DRUG TARGETING OF A PEPTIDE RADIOPHARMACEUTICAL THROUGH THE PRIMATE BLOOD-BRAIN BARRIER IN VIVO WITH A MONOCLONAL ANTIBODY TO THE HUMAN INSULIN RECEPTOR

摘要

[<125>I]-A beta <1-40> was mono-biotinylated and conjugated to a blood-brain barrier drug delivery and brain targeting system comprised of a complex of the 83-14 monoclonal antibody (MAb) to the human insulin receptor, which is tagged with streptavidin (SA) to produce a marked increase in rhesus monkey brain uptake of the [<125>I]-bio-A beta <1-40> at 3 hours following intravenous injection compared to no measurable brain uptake of [<125>I]-bio-A beta <1-40> in the absence of a BBB drug.